Brief Summary
This study will investigate the safety, tolerability, and antitumor activity of S095029 (anti-NKG2A antibodya protein made by the immune system to fight against harmful substances (antigens), such as bacteria or viruses) in combination with pembrolizumab in in microsatellite instability-high/Defective mismatch repair (MSI-H/dMMR) locally advancedat a late stage, far along unresectable or metastatic gastric /GEJ adenocarcinomas.
Intervention / Treatment
- Drug: S095029
- Drug: pembrolizumab 200 mg (KEYTRUDA ®)
Inclusion Criteria:
- Have a confirmed diagnosisthe process of identifying a disease based on signs and symptoms, patient history and medical test results of locally advanced and unresectable or metastatic gastric or gastro-esophageal junction adenocarcinomacancer arising from mucus-producing glands in organs
- Participants’ tumor must have an MSI-H/dMMR status according to institutional guidelines and/or according to the College of American Pathologists, determined at any time prior to enrolment.